The Technical Analyst
Assembly Biosciences Inc [ASMB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Assembly Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.29% $13.05
America/New_York / 23 apr 2024 @ 15:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 71.55 mill |
| EPS: | -13.38 |
| P/E: | -0.980 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 5.48 mill |
| Avg Daily Volume: | 0.0276 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.980 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -0.980 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.273 (-90.25%) $-11.78 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 12.35 - 13.75 ( +/- 5.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Mchutchison John G | Sell | 1 206 | Common Stock |
| 2024-03-29 | Bjorkquist Jeanette M | Buy | 850 | Common Stock |
| 2024-04-01 | Bjorkquist Jeanette M | Sell | 114 | Common Stock |
| 2024-03-29 | Bjorkquist Jeanette M | Buy | 1 550 | Stock Option (right to buy) |
| 2024-03-29 | White Nicole S | Buy | 17 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 65.43 |
| Last 96 transactions |
| Buy: 4 380 980 | Sell: 646 377 |
Forecast:
16:00 - $13.05
Live Trading Signals (every 1 min)
Forecast
1: 15:28 - $13.06
Forecast 2: 16:00 - $13.05
Forecast 3: 16:00 - $13.05
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.05 (-1.29% ) |
| Volume | 0.0117 mill |
| Avg. Vol. | 0.0276 mill |
| % of Avg. Vol | 42.23 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ASMB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ASMB
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Assembly Biosciences Reports Fourth Quarter And Year End 2023 Financial Results And Recent Highlights
South san francisco, calif., march 28, 2024 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended december 31, 2023.
2024-02-08 08:00:00 - Press Release
Assembly Biosciences Announces Effective Date Of Reverse Stock Split
– assembly bio common stock expected to begin trading on a split-adjusted basis on february 12, 2024 –
2024-01-04 08:00:00 - Press Release
Assembly Biosciences Provides Anticipated Development Milestones For 2024
South san francisco, calif., jan. 04, 2024 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
2023-11-10 16:05:00 - Press Release
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif., nov. 10, 2023 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, anuj gaggar, md, phd on november 8, 2023.
2023-11-08 08:00:00 - Press Release
Assembly Biosciences Names Anuj Gaggar, Md, Phd, As Chief Medical Officer
-- dr. gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- south san francisco, calif., nov. 08, 2023 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that anuj gaggar, md, phd, has joined the company as chief medical officer. dr. gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis b virus (hbv), hepatitis c virus (hcv) and hepatitis d virus (hdv) infections.
Latest News
2023-11-24 09:50:02 - PennyStocks
5 Penny Stocks With Big Black Friday Stock Market News
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains.
2023-10-17 10:59:57 - InvestorPlace
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies have entered into a 12-year partnership agreement.
2023-05-23 16:05:00 - GlobeNewsWire
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
2022-12-19 09:33:00 - PennyStocks
Penny Stocks To Buy Now? 6 To Watch With Big News Today
2022-11-09 11:18:08 - Zacks Investment Research
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-10-24 08:00:00 - GlobeNewsWire
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio
2022-08-04 13:32:31 - Zacks Investment Research
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-08-04 07:32:05 - Zacks Investment Research
New Strong Buy Stocks for August 4th
ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.
2022-06-22 07:00:55 - InvestorPlace
7 Penny Stocks That Could Triple in 2022
Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That Could Triple in 2022 appeared first on InvestorPlace.
2022-06-21 08:00:00 - GlobeNewsWire
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor (IFNAR) agonist designed to selectively activate the interferon-α pathway within the liver and offer the convenience of oral dosing.